Company Description
ADC Therapeutics SA is a clinical-stage biotechnology company. It engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its clinical-stage product candidates include loncastuximab tesirine, ca...
ADC Therapeutics SA is a clinical-stage biotechnology company. It engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its clinical-stage product candidates include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. The company was founded by Christopher Martin on June 6, 2011 and is headquartered in Epalinges, Switzerland.
Valuation
Price to Sales Ratio
1.43
Enterprise Value to EBITDA
0.40
Enterprise Value to Sales
-0.23
Total Debt to Enterprise Value
1.29
Efficiency
Receivables Turnover
4.04
Total Asset Turnover
0.37
Liquidity
Current Ratio
4.51
Quick Ratio
4.32
Cash Ratio
3.30
Profitability
Gross Margin
97.82
Operating Margin
-58.90
Pretax Margin
-73.68
Net Margin
-74.22
Return on Assets
-27.16
Return on Equity
-122.28
Return on Total Capital
-48.30
Return on Invested Capital
-63.50
Capital Structure
Total Debt to Total Equity
132.29
Total Debt to Total Capital
56.95
Total Debt to Total Assets
22.18
Long-Term Debt to Equity
116.99
Long-Term Debt to Total Capital
50.37
Officers and Executives
| Name | Age | Officer Since | Title |
|---|---|---|---|
| Mr. Ron Squarer | 54 | 2020 | Chairman |
| Mr. Ameet Mallik | 49 | 2022 | President & Chief Executive Officer |
| Mr. Jose Carmona | 50 | 2022 | Chief Financial Officer |
| Dr. Michael Mulkerrin | - | - | Chief Technical Operations Officer |
| Dr. Mohamed Zaki | - | 2023 | Chief Medical Officer |
Insider Actions
MarketWatch News on ADCT
-
ADC Therapeutics started at hold with $42 stock price target at Stifel Nicolaus
- Tomi Kilgore
-
ADC Therapeutics stock soars 56% in trading debut
- Ciara Linnane
-
ADC Therapeutics stock soars 52% in trading debut
- Ciara Linnane
-
ADC Therapeutics sets IPO terms to raise up to $185.3 million
- Tomi Kilgore
-
ADC Therapeutics sets IPO terms, to offer 8.1 mln shares priced at $23 to $26 each
- Ciara Linnane
Other News on ADCT
-
FDA Takes Tougher Line on Fast-Tracked Drugs
- The Wall Street Journal Interactive Edition
-
ADC Therapeutics SA (ADCT) Q3 2022 Earnings Call Transcript
- Seeking Alpha
- Loading more headlines...
